8-K: 23andMe Sells Core Assets to Founder's Nonprofit for $305 Million Amidst Bankruptcy

23andMe Holding Co. has agreed to sell substantially all of its assets, including its Personal Genome Service and Research Services, to TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki, for $305 million in cash, following a competitive bidding process during its Chapter 11 bankruptcy.

Summary

• 23andMe Holding Co. (the 'Company') and its subsidiaries ('Debtors') are undergoing Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri.
• The Debtors conducted an auction for the sale of substantially all of their assets, including the Personal Genome Service (PGS) and Research Services business lines, and the Lemonaid Health business.
• Initially, Regeneron Pharmaceuticals, Inc. was selected as the successful bidder on May 17, 2025, with a purchase price of $256.0 million.
• Following this, TTAM Research Institute, an affiliate of 23andMe co-founder Anne Wojcicki, submitted a higher bid of $305.0 million.
• A final round of bidding was conducted on June 13, 2025, where TTAM Research Institute was selected as the winning bidder for $305.0 million in cash, plus the assumption of specified liabilities and cure payments.
• Regeneron Pharmaceuticals, Inc. is now the next-highest or backup bidder with a purchase price of $151.0 million.
• The Regeneron Asset Purchase Agreement was terminated on June 13, 2025, with 23andMe retaining $15.1 million of Regeneron's earnest deposit.
• TTAM Research Institute also agreed to acquire the Company's telehealth services business (Lemonaid Health, Inc.) for an additional $2.5 million.
• The transaction with TTAM is subject to Court approval, with a hearing scheduled for June 17, 2025, and customary closing conditions.
• TTAM has committed to enhanced customer data privacy and protection measures, including honoring existing data rights, customer notification, data transfer restrictions, establishing a Privacy Advisory Board, implementing privacy procedures, offering two years of free Experian identity theft monitoring, and continuing de-identified data use for scientific research.
• 23andMe's Class A common stock was delisted from Nasdaq and began trading on the OTC Pink Market under the symbol MEHCQ on March 31, 2025.
• The Company cautions that trading in its common stock during Chapter 11 is highly speculative and poses substantial risks, with trading prices potentially bearing little or no relationship to actual recovery for common stock holders.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the company's Chapter 11 bankruptcy, delisting from Nasdaq, and explicit warnings about potential zero recovery for common stock holders. While the asset sale price increased, this is a positive for creditors, not necessarily for existing shareholders. The privacy commitments are positive for customers but do not offset the severe financial distress for investors.

Positives

• The competitive bidding process resulted in a significantly higher purchase price for the assets, increasing from an initial $256.0 million to $305.0 million, providing more value to stakeholders.
• The winning bidder, TTAM Research Institute, is led by 23andMe co-founder Anne Wojcicki, which management believes aligns with the Company's founding vision and mission.
• TTAM Research Institute has made binding commitments to enhance customer data privacy and protection, including honoring existing data rights, providing customer notification, restricting data transfers, establishing a Privacy Advisory Board, implementing privacy procedures, offering two years of free Experian identity theft monitoring, and continuing de-identified data use for scientific research.
• The sale of the telehealth services business (Lemonaid Health) for an additional $2.5 million ensures continuity for this segment.

Negatives

• The Company is operating under Chapter 11 bankruptcy protection, indicating significant financial distress.
• The Class A common stock has been delisted from Nasdaq and is now trading on the OTC Pink Market, which typically implies lower liquidity and transparency.
• The Company explicitly cautions that trading in its common stock during bankruptcy is highly speculative and poses substantial risks, with trading prices potentially bearing little or no relationship to actual recovery for common stock holders.
• The transaction is still subject to Court approval and customary closing conditions, introducing a degree of uncertainty.
• If the TTAM transaction is not consummated, the Debtors will seek authorization to proceed with the Regeneron agreement, but at a significantly lower purchase price of $151.0 million, which would be a substantial negative outcome.

Risks

• Risks and uncertainties relating to the Chapter 11 Cases, including obtaining Court approval for motions.
• The effects of the Chapter 11 Cases on the Company and the interests of various constituents.
• Court rulings in the Chapter 11 Cases and the general outcome of the cases.
• The Debtors' ability to complete the sale of substantially all assets under Section 363 of the Bankruptcy Code.
• The length of time the Company will operate under the Chapter 11 Cases.
• Risks associated with any third-party motions in the Chapter 11 Cases.
• Potential adverse effects of the Chapter 11 Cases on the Company's liquidity or results of operations.
• Increased legal and other professional costs necessary to execute the Company's reorganization.
• Uncertainty regarding whether the Company will emerge, in whole or in part, from the Chapter 11 Cases as a going concern.
• Trading price and volatility of the Common Stock.
• Continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes, whether trading volume will be sufficient for an efficient market, and whether quotes will continue in the future.
• The TTAM Asset Purchase Agreement contains certain termination rights for TTAM and the Debtors, including if the closing date has not occurred by September 1, 2025 (or December 1, 2025, in certain circumstances).
• The TTAM Asset Purchase Agreement can be terminated if the Court dismisses or converts the Chapter 11 Cases to a Chapter 7 case.
• The TTAM Asset Purchase Agreement can be terminated if the Court denies approval of the Sale or Sale Order.

Future Outlook

The Company expects the transaction with TTAM Research Institute to close in the coming weeks, subject to Court approval. If the TTAM transaction is not consummated, the Debtors will seek Court authorization to proceed with the Regeneron Asset Purchase Agreement. The Company's common stock will continue to trade on the OTC Pink Market, but its future trading volume and the continuation of quotes are uncertain. The Company's ability to emerge from Chapter 11 as a going concern is also a forward-looking uncertainty.

Management Comments

• "We are pleased that the competitive bidding process has resulted in significantly more value to our stakeholders while enhancing critical protections around customer privacy, choice and consent with respect to their genetic data." Mark Jensen, Chair of the Board and member of the Special Committee of the Board of Directors of 23andMe.
• "As 23andMe’s founder, Ms. Wojcicki is well positioned to advance the Company’s founding vision of helping people access, understand and gain health benefits through greater understanding of the human genome. We will work to complete the transaction quickly so that 23andMe can begin its next chapter as a nonprofit." Mark Jensen.
• "I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome. We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish." Anne Wojcicki.
• "The 23andMe community of consented individuals will also have the opportunity to be part of making novel genetic discoveries that improve our knowledge of DNA – the code of life – and the health and wellness of everyone. I remain committed to the 23andMe community and driving forward this mission. The future of healthcare belongs to all of us." Anne Wojcicki.

Industry Context

This announcement reflects the ongoing challenges faced by direct-to-consumer genomics companies, particularly those that expanded into broader healthcare services. The sale of core assets through bankruptcy highlights the difficulty in monetizing genetic data and consumer health services in a sustainable way. The acquisition by a nonprofit led by the founder, with a strong emphasis on privacy and research, suggests a potential shift in the business model from a for-profit, publicly traded entity to a mission-driven research organization, which could set a precedent for how valuable genetic data assets are managed in distressed situations. The emphasis on privacy commitments by TTAM also reflects increasing consumer and regulatory scrutiny on data handling in the genomics and health tech sectors.

Comparison to Industry Standards

• The sale of 23andMe's core assets through a Chapter 11 bankruptcy process is a significant event, contrasting sharply with the growth and expansion strategies seen in more successful or well-capitalized genomics and biotech firms like Illumina (focused on sequencing technology) or large pharmaceutical companies like Regeneron (which was a bidder here, indicating interest in the data assets but not at the higher price).
• The valuation of $305 million for substantially all assets, including the Personal Genome Service and Research Services, provides a market-driven benchmark for a distressed sale of a consumer genomics company with a large dataset. This can be compared to the valuations of other private or public genomics companies, though direct comparisons are difficult given the unique circumstances of a bankruptcy sale.
• The emphasis on enhanced privacy safeguards by TTAM, including a Privacy Advisory Board and specific data handling commitments, sets a high standard for consumer genomics data stewardship, potentially exceeding the current baseline practices of some industry players, especially given the context of a distressed asset sale where data integrity could be compromised.
• The transition of a publicly traded company's core assets to a nonprofit entity is an unusual outcome in the industry, differing from typical mergers, acquisitions, or private equity buyouts seen for companies like Ancestry.com (acquired by Blackstone) or MyHeritage (acquired by Francisco Partners), which remained for-profit entities.

Legal Proceedings

• The Company and its subsidiaries filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of Missouri (the Chapter 11 Cases).

Related Party Transactions

• TTAM Research Institute, the winning bidder for the assets, is an affiliate of Anne Wojcicki, the Company's co-founder, former chief executive officer, and current member of the Company's Board of Directors.

Stakeholder Impact

• Shareholders: Face substantial risks, with trading in Class A common stock being highly speculative and potentially bearing little or no relationship to actual recovery, implying a high likelihood of significant or total loss.
• Customers: Will continue to receive Personal Genome Service and Research Services under TTAM, with enhanced privacy protections and commitments, including data rights, notification, and identity theft monitoring.
• Creditors: The bankruptcy process and asset sale are intended to maximize recovery for creditors, with the increased sale price benefiting them.
• Employees: Not explicitly mentioned, but asset sales in bankruptcy often lead to workforce restructuring or transfers.

Next Steps

• A Court hearing is scheduled for June 17, 2025, to consider approval of the TTAM Asset Purchase Agreement and the Transaction.
• The transaction is expected to close in the coming weeks, subject to Court approval and customary closing conditions.
• If the TTAM transaction is not consummated, the Debtors will seek Court authorization to proceed with the Regeneron Asset Purchase Agreement.
• TTAM Research Institute will establish a Consumer Privacy Advisory Board within 90 days of the closing of the transaction.
• TTAM will implement privacy procedures, notify customers of material changes, mitigate data breaches, and prepare annual reports to be made available to Attorneys General upon request.
• TTAM will offer customers two years of free Experian identity theft monitoring.

Key Dates

Recommendation

Keywords

23andMe, TTAM Research Institute, Regeneron Pharmaceuticals, Chapter 11 bankruptcy, asset sale, Personal Genome Service, Lemonaid Health, genetic data, privacy policy, OTC Pink Market, corporate restructuring, biotechnology, human genetics, Anne Wojcicki, bankruptcy court, asset purchase agreement